Construction of a Nomogram for Identifying Refractory Mycoplasma pneumoniae Pneumonia Among Macrolide-Unresponsive Mycoplasma pneumoniae Pneumonia in Children

References

• Lanks CW, Musani AI, Hsia DW. Community-acquired pneumonia and hospital-acquired pneumonia. Med Clin North Am. 2019;103(3):487–501. doi:10.1016/j.mcna.2018.12.008
   PubMed Web of Science ®Google Scholar
• Hung HM, Chuang CH, Chen YY, et al. Clonal spread of macrolide-resistant Mycoplasma pneumoniae sequence type-3 and type-17 with recombination on non-P1 adhesin among children in Taiwan. Clin Microbiol Infect. 2021;27(8):1169.e1161–1169.e1166. doi:10.1016/j.cmi.2020.09.035
   Web of Science ®Google Scholar
• Wu TH, Wang NM, Liu FC, et al. Macrolide resistance, clinical features, and cytokine profiles in Taiwanese children with Mycoplasma pneumoniae infection. Open Forum Infect Dis. 2021;8(9):ofab416.
   PubMed Web of Science ®Google Scholar
• Waites KB, Xiao L, Liu Y, Balish MF, Atkinson TP. Mycoplasma pneumoniae from the respiratory tract and beyond. Clin Microbiol Rev. 2017;30(3):747–809.
   PubMed Web of Science ®Google Scholar
• Kim SH, Lee E, Song ES. Clinical significance of pleural effusion in mycoplasma pneumoniae pneumonia in children. Pathogens. 2021;10(9):1.
   Web of Science ®Google Scholar
• Narita M. Classification of extrapulmonary manifestations due to mycoplasma pneumoniae infection on the basis of possible pathogenesis. Front Microbiol. 2016;7:23.
   PubMed Web of Science ®Google Scholar
• Amza A, Kadri B, Nassirou B, et al. Community-level association between clinical trachoma and ocular chlamydia infection after MASS azithromycin distribution in a mesoendemic region of Niger. Ophthalmic Epidemiol. 2019;26(4):231–237.
   PubMed Web of Science ®Google Scholar
• Levine A, Kori M, Kierkus J, et al. Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn’s disease: a randomised controlled trial. Gut. 2019;68(2):239–247.
   PubMed Web of Science ®Google Scholar
• Waites KB, Crabb DM, Duffy LB. Comparative in vitro susceptibilities of human Mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. Antimicrob Agents Chemother. 2009;53(5):2139–2141.
   PubMed Web of Science ®Google Scholar
• Yang HJ. Benefits and risks of therapeutic alternatives for macrolide resistant Mycoplasma pneumoniae pneumonia in children. Korean J Pediatr. 2019;62(6):199–205. doi:10.3345/kjp.2018.07367
   PubMedGoogle Scholar
• Qu J, Chen S, Bao F, Gu L, Cao B. Molecular characterization and analysis of Mycoplasma pneumoniae among patients of all ages with community-acquired pneumonia during an epidemic in China. Int J Infect Dis. 2019;83:26–31. doi:10.1016/j.ijid.2019.03.028
   PubMed Web of Science ®Google Scholar
• Waites KB, Ratliff A, Crabb DM, et al. Macrolide-resistant Mycoplasma pneumoniae in the United States as determined from a national surveillance program. J Clin Microbiol. 2019;57(11):2. doi:10.1128/JCM.00968-19
   Web of Science ®Google Scholar
• Pereyre S, Goret J, Bébéar C. Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment. Front Microbiol. 2016;7:974. doi:10.3389/fmicb.2016.00974
   PubMed Web of Science ®Google Scholar
• Chen YC, Hsu WY, Chang TH. Macrolide-resistant Mycoplasma pneumoniae infections in pediatric community-acquired pneumonia. Emerg Infect Dis. 2020;26(7):1382–1391. doi:10.3201/eid2607.200017
   PubMed Web of Science ®Google Scholar
• Hsieh YC, Tsao KC, Huang CG, et al. Life-threatening pneumonia caused by macrolide-resistant Mycoplasma pneumoniae. Pediatr Infect Dis J. 2012;31(2):208–209. doi:10.1097/INF.0b013e318234597c
   PubMed Web of Science ®Google Scholar
• Tsai TA, Tsai CK, Kuo KC, Yu HR. Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children. J Microbiol Immunol Infect. 2021;54(4):557–565. doi:10.1016/j.jmii.2020.10.002
   PubMedGoogle Scholar
• Aliberti S, Dela Cruz CS, Amati F, Sotgiu G, Restrepo MI. Community-acquired pneumonia. Lancet. 2021;398(10303):906–919. doi:10.1016/S0140-6736(21)00630-9
   PubMed Web of Science ®Google Scholar
• Uehara S, Sunakawa K, Eguchi H, et al. Japanese guidelines for the management of respiratory infectious diseases in children 2007 with focus on pneumonia. Pediatr Int. 2011;53(2):264–276. doi:10.1111/j.1442-200X.2010.03316.x
   PubMed Web of Science ®Google Scholar
• Tong L, Huang S, Zheng C, Zhang Y, Chen Z. Refractory Mycoplasma pneumoniae pneumonia in children: early recognition and management. J Clin Med. 2022;11(10):1. doi:10.3390/jcm11102824
   Web of Science ®Google Scholar
• Sánchez AR, Rogers RS 3rd, Sheridan PJ. Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity. Int J Dermatol. 2004;43(10):709–715. doi:10.1111/j.1365-4632.2004.02108.x
   PubMed Web of Science ®Google Scholar
• Kawai Y, Miyashita N, Kubo M, et al. Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. Antimicrob Agents Chemother. 2013;57(5):2252–2258. doi:10.1128/AAC.00048-13
   PubMed Web of Science ®Google Scholar
• Grady RW. Systemic quinolone antibiotics in children: a review of the use and safety. Expert Opin Drug Saf. 2005;4(4):623–630. doi:10.1517/14740338.4.4.623
   PubMedGoogle Scholar
• Ha SG, Oh KJ, Ko K-P. Therapeutic efficacy and safety of prolonged macrolide, corticosteroid, doxycycline, and levofloxacin against macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children. J Korean Med Sci. 2018;33(43):e268. doi:10.3346/jkms.2018.33.e268
   PubMed Web of Science ®Google Scholar
• Lai JF, Zindl CL, Duffy LB, et al. Critical role of macrophages and their activation via MyD88-NFκB signaling in lung innate immunity to Mycoplasma pneumoniae. PLoS One. 2010;5(12):e14417. doi:10.1371/journal.pone.0014417
   PubMed Web of Science ®Google Scholar
• Roifman CM, Rao CP, Lederman HM, et al. Increased susceptibility to Mycoplasma infection in patients with hypogammaglobulinemia. Am J Med. 1986;80(4):590–594. doi:10.1016/0002-9343(86)90812-0
   PubMed Web of Science ®Google Scholar
• Foy HM, Ochs H, Davis SD, Kenny GE, Luce RR. Mycoplasma pneumoniae infections in patients with immunodeficiency syndromes: report of four cases. J Infect Dis. 1973;127(4):388–393. doi:10.1093/infdis/127.4.388
   PubMed Web of Science ®Google Scholar
• Wang M, Wang Y, Yan Y, et al. Clinical and laboratory profiles of refractory Mycoplasma pneumoniae pneumonia in children. Int J Infect Dis. 2014;29:18–23. doi:10.1016/j.ijid.2014.07.020
   PubMed Web of Science ®Google Scholar
• Metzemaekers M, Gouwy M, Proost P. Neutrophil chemoattractant receptors in health and disease: double-edged swords. Cell Mol Immunol. 2020;17(5):433–450.
   PubMed Web of Science ®Google Scholar
• Liew PX, Kubes P. The neutrophil’s role during health and disease. Physiol Rev. 2019;99(2):1223–1248.
   PubMed Web of Science ®Google Scholar
• Silvestre-Roig C, Hidalgo A, Soehnlein O. Neutrophil heterogeneity: implications for homeostasis and pathogenesis. Blood. 2016;127(18):2173–2181.
   PubMed Web of Science ®Google Scholar
• Headland SE, Norling LV. The resolution of inflammation: principles and challenges. Semin Immunol. 2015;27(3):149–160.
   PubMed Web of Science ®Google Scholar
• Rossaint J, Margraf A, Zarbock A. Role of platelets in leukocyte recruitment and resolution of inflammation. Front Immunol. 2018;9:2712.
   PubMed Web of Science ®Google Scholar
• Chen Z, Shao X, Dou X, et al. Role of the Mycoplasma pneumoniae/Interleukin-8/neutrophil axis in the pathogenesis of pneumonia. PLoS One. 2016;11(1):e0146377.
   PubMed Web of Science ®Google Scholar
• Piacentini E, Sánchez B, Arauzo V, et al. Procalcitonin levels are lower in intensive care unit patients with H1N1 influenza A virus pneumonia than in those with community-acquired bacterial pneumonia. A pilot study. J Crit Care. 2011;26(2):201–205.
   PubMed Web of Science ®Google Scholar
• Cao X. Monitoring mycoplasma pneumoniae-specific antibody, C-reactive protein, and procalcitonin levels in children with Mycoplasma pneumonia is important. Comput Math Methods Med. 2022;2022:7976858.
   PubMed Web of Science ®Google Scholar
• Liu TY, Lee WJ, Tsai CM, et al. Serum lactate dehydrogenase isoenzymes 4 plus 5 is a better biomarker than total lactate dehydrogenase for refractory Mycoplasma pneumoniae pneumonia in children. Pediatr Neonatol. 2018;59(5):501–506.
   PubMed Web of Science ®Google Scholar
• Lu A, Wang C, Zhang X, Wang L, Qian L. Lactate dehydrogenase as a biomarker for prediction of refractory Mycoplasma pneumoniae pneumonia in children. Respir Care. 2015;60(10):1469–1475.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhou Y, Li S, et al. The clinical characteristics and predictors of refractory Mycoplasma pneumoniae pneumonia in children. PLoS One. 2016;11(5):e0156465.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Mei S, Zhou Y, et al. Cytokines as the good predictors of refractory Mycoplasma pneumoniae pneumonia in school-aged children. Sci Rep. 2016;6:37037.
   PubMed Web of Science ®Google Scholar
• Wen J, Su Y, Sun H, et al. The combination of initial markers to predict refractory Mycoplasma pneumoniae pneumonia in Chinese children: a case control study. Respir Res. 2021;22(1):89.
   PubMed Web of Science ®Google Scholar
• Cheng S, Lin J. Development and validation of a simple-to-use nomogram for predicting refractory Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol. 2020;55(4):968–974.
   PubMed Web of Science ®Google Scholar
• Shen F, Dong C, Zhang T, et al. Development of a nomogram for predicting refractory Mycoplasma pneumoniae pneumonia in children. Front Pediatr. 2022;10:813614.
   PubMed Web of Science ®Google Scholar